• Last active: 4 months ago
  • 25 members
  • 0 posts
TrialSite News
  • Group
  • Daniel OConnor
  • TrialSite brings a much-needed independent, objective, and unbiased media and analysis to medical research. As populations age, the need for new health products and services comes. With the move to value-based care in the United States for example comes the need for more empowered and informed consumers and patients. TrialSite publishes complex medical research for viewing by a wide range of subscribers from busy physicians and other health care professionals to patients (and family members) to industry and investors. TrialSite’s leadership continues to advance the proprietary media and social authoring platform to extend and enhance how people can share and access unbiased research information from clinical trial results to university drug discovery efforts to private equity investments in emerging science. The founder, Daniel O’Conner fully financed the company from the end of 2018 until August 2021 when it set up a paywall. A “paywall” is a method of restricting access to content to those who purchase or pay a subscription fee. Now generating revenues, the Company intends to expand to include transparent unbiased news and information for life science investors, from private equity and VCs to institutional investors placing investments in life sciences companies. TrialSite tracks the entire ecosystem not holding back or filtering information like many other media. Moreover, we are continuously advancing the proprietary technology behind TrialSite. We have included features such as social authoring (similar to Substack or Medium) and will soon release a dynamic Q&A feature. Our goal is to continuously add compelling features to the platform so that over time it becomes a unique media and social network dedicated to medical research. Funding will help A) accelerate new features, B) expand our coverage into life science investment, and C) support subscription marketing efforts. In a few short years, with little marketing and one founder/financier, TrialSite has become a well-known and increasingly global brand. We seek to use the funds from this financing to continue to A) enhance the product (user/reader experience) and add more engagement features to deliver a unique asset combining elements of media, social authoring network (similar to Substack, Inc.), B) expand coverage to include investor community and C) expand marketing to drive more subscriptions. We hope to make TrialSite a digital hub where valuable stakeholders in the global life science community come to learn, contribute and engage from health care professionals and industry to the patient advocacy community and investors With additional funds, we hope to have 10,000 subscribers by the end of 2022 reaching between $500K to $1M in revenue. We will strive to grow to 25,000 subscribers by the end of 2023 approaching $2M in revenue. As we segment the media sections including various disease/therapeutic areas (patients, doctors, and other health care professionals, regulators, etc.) we hope to also build out the most robust, specialized investor-targeted media and social network for health & life sciences research. We believe we are poised to take off and grow with support.

WHEN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING. THIS INCLUDES ANALYZING THE MERITS AND RISKS INVOLVED WITH INVESTING IN THE OFFERING. INVESTMENTS ON PICMII CROWDFUNDING ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK. THIS RISK INCLUDES THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

Unless otherwise stated all securities-related activity is conducted by PicMii Crowdfunding, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and a member of the Financial Industry Regulatory Authority (FINRA). PicMii Crowdfunding, LLC is not a registered broker-dealer and all activity involving escrow/holding funds is performed by Prime Trust, an escrow agent registered with the U.S. Security and Exchange Commission.

Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to both accredited and non-accredited investors, are made through PicMii Crowdfunding, LLC. Although these offerings are open to the general public, all securities offered on PicMii Crowdfunding have not been recommended or approved by any federal or state securities commission or regulatory authority. PicMii Crowdfunding does not provide any investment advice and does not provide any legal or tax advice with respect to any securities. All securities listed on The Platform are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. PicMii Crowdfunding does not verify the adequacy, accuracy or completeness of any information provided by the issuer. Neither PicMii Crowdfunding, nor any of its officers, directors, agents and employees makes any warranty, expressed or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this website or the use of information on this website.

By accessing this site and any pages on this site, you agree to be bound by our Terms of Use and Privacy Policy which may be amended at any time without notice or liability.

Yes No